Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.6843
USD
|
-2.24%
|
|
+3.52%
|
-7.90%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
752
|
754
|
651.1
|
577.1
|
40.48
|
37.41
|
-
|
-
|
Enterprise Value (EV)
1 |
752
|
754
|
484.1
|
431.7
|
-60.28
|
27.01
|
66.51
|
-60.79
|
P/E ratio
|
-6.47
x
|
84.1
x
|
-7
x
|
-6.75
x
|
-0.34
x
|
-0.63
x
|
-0.67
x
|
-0.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
37.8
x
|
5.58
x
|
28.3
x
|
13.8
x
|
1.93
x
|
6.69
x
|
10.2
x
|
9.92
x
|
EV / Revenue
|
37.8
x
|
5.58
x
|
21
x
|
10.3
x
|
-2.87
x
|
4.83
x
|
18.1
x
|
-16.1
x
|
EV / EBITDA
|
-6.75
x
|
135
x
|
-5.45
x
|
-4.95
x
|
-
|
-0.46
x
|
-1.22
x
|
1.25
x
|
EV / FCF
|
-6.88
x
|
-129
x
|
-8.05
x
|
-5.48
x
|
-
|
-0.49
x
|
-1.68
x
|
2.68
x
|
FCF Yield
|
-14.5%
|
-0.77%
|
-12.4%
|
-18.2%
|
-
|
-204%
|
-59.4%
|
37.3%
|
Price to Book
|
-
|
-
|
2.86
x
|
3.64
x
|
0.7
x
|
3.6
x
|
-1.63
x
|
0.48
x
|
Nbr of stocks (in thousands)
|
46,679
|
49,832
|
53,459
|
53,734
|
54,481
|
54,667
|
-
|
-
|
Reference price
2 |
16.11
|
15.13
|
12.18
|
10.74
|
0.7430
|
0.6843
|
0.6843
|
0.6843
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
19.89
|
135.1
|
23.03
|
41.87
|
20.97
|
5.589
|
3.669
|
3.772
|
EBITDA
1 |
-111.5
|
5.594
|
-88.84
|
-87.29
|
-
|
-58.29
|
-54.52
|
-48.56
|
EBIT
1 |
-111.7
|
5.385
|
-89.08
|
-87.54
|
-121.5
|
-64
|
-66.23
|
-62.66
|
Operating Margin
|
-561.6%
|
3.99%
|
-386.85%
|
-209.08%
|
-579.43%
|
-1,145.25%
|
-1,804.87%
|
-1,661.37%
|
Earnings before Tax (EBT)
1 |
-107.2
|
7.719
|
-88.44
|
-85.47
|
-118.5
|
-63.57
|
-66.91
|
-62.41
|
Net income
1 |
-106.4
|
8.41
|
-88.44
|
-85.47
|
-118.5
|
-63.57
|
-66.91
|
-62.41
|
Net margin
|
-534.91%
|
6.23%
|
-384.06%
|
-204.16%
|
-565.21%
|
-1,137.54%
|
-1,823.46%
|
-1,654.59%
|
EPS
2 |
-2.490
|
0.1800
|
-1.740
|
-1.590
|
-2.190
|
-1.088
|
-1.018
|
-0.7525
|
Free Cash Flow
1 |
-109.2
|
-5.836
|
-60.13
|
-78.77
|
-
|
-55.2
|
-39.5
|
-22.7
|
FCF margin
|
-549.35%
|
-4.32%
|
-261.1%
|
-188.15%
|
-
|
-987.73%
|
-1,076.47%
|
-601.83%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
20.27
|
0.821
|
4.79
|
23
|
10.81
|
3.261
|
6.165
|
6.933
|
4.866
|
3.004
|
1.69
|
1.443
|
1.343
|
1.113
|
1.2
|
EBITDA
1 |
-1.062
|
-33.46
|
-27.85
|
-4.409
|
-23.78
|
-31.25
|
-27.59
|
-32.28
|
-28.84
|
-
|
-22.18
|
-12.95
|
-11.71
|
-11.45
|
-
|
EBIT
1 |
-1.124
|
-33.52
|
-27.91
|
-4.472
|
-23.84
|
-31.31
|
-27.65
|
-32.34
|
-28.9
|
-32.61
|
-21.58
|
-13.56
|
-12.56
|
-13.75
|
-16.5
|
Operating Margin
|
-5.54%
|
-4,083.07%
|
-582.69%
|
-19.44%
|
-220.52%
|
-960.04%
|
-448.5%
|
-466.46%
|
-593.88%
|
-1,085.45%
|
-1,276.98%
|
-939.77%
|
-935.34%
|
-1,235.6%
|
-1,375%
|
Earnings before Tax (EBT)
1 |
-1.013
|
-33.38
|
-27.75
|
-4.206
|
-23.18
|
-30.34
|
-26.66
|
-31.48
|
-28.03
|
-32.34
|
-21.59
|
-13.9
|
-13.28
|
-14.82
|
-16.2
|
Net income
1 |
-1.013
|
-33.38
|
-27.75
|
-4.206
|
-23.18
|
-30.34
|
-26.66
|
-31.48
|
-28.03
|
-32.34
|
-21.59
|
-13.9
|
-13.28
|
-14.82
|
-16.2
|
Net margin
|
-5%
|
-4,066.02%
|
-579.31%
|
-18.28%
|
-214.37%
|
-930.36%
|
-432.52%
|
-454.05%
|
-576.08%
|
-1,076.46%
|
-1,277.74%
|
-963.46%
|
-989.07%
|
-1,331.48%
|
-1,350%
|
EPS
2 |
-0.0200
|
-0.6300
|
-0.5200
|
-0.0800
|
-0.4300
|
-0.5600
|
-0.4900
|
-0.5800
|
-0.5200
|
-0.5900
|
-0.3925
|
-0.2525
|
-0.2225
|
-0.2400
|
-0.2900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
3/1/22
|
5/9/22
|
8/8/22
|
11/7/22
|
3/6/23
|
5/15/23
|
8/7/23
|
11/13/23
|
3/4/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
29.1
|
-
|
Net Cash position
1 |
-
|
-
|
167
|
145
|
101
|
10.4
|
-
|
98.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.5337
x
|
-
|
Free Cash Flow
1 |
-109
|
-5.84
|
-60.1
|
-78.8
|
-
|
-55.2
|
-39.5
|
-22.7
|
ROE (net income / shareholders' equity)
|
-66.4%
|
3.86%
|
-37.1%
|
-44.3%
|
-110%
|
-185%
|
-
|
-103%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-34.1%
|
-39.8%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
259.1
|
214.6
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
4.250
|
2.950
|
1.050
|
0.1900
|
-0.4200
|
1.440
|
Cash Flow per Share
2 |
-
|
-0.1200
|
-
|
-1.470
|
-
|
-0.9700
|
-0.6600
|
-0.2900
|
Capex
1 |
0.02
|
0.35
|
0.04
|
0.04
|
-
|
1.65
|
1.65
|
1.65
|
Capex / Sales
|
0.09%
|
0.26%
|
0.17%
|
0.1%
|
-
|
29.52%
|
44.97%
|
43.75%
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Last Close Price
0.6843
USD Average target price
5.12
USD Spread / Average Target +648.21% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.90% | 37.41M | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.35B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|